Approximately 84.8 million people live with asthma and chronic obstructive pulmonary disease (COPD) in Europe^1,2. These chronic respiratory diseases result in substantial clinical and economic burden³, with 9.7 million healthy years lost annually^1,2. The majority of these patients have inadequately managed disease^4,5, which often reflects poor inhaler adherence and technique^6–10. Good inhaler use is important as poor inhaler mastery is associated with increased morbidity and hospitalisations¹¹. As healthcare professional- and self-assessed inhaler use may not reflect real-life scenarios¹², it is important that accurate means of measuring patients’ inhaler adherence and technique are developed to improve disease management.

To learn more about unmet needs in asthma and COPD, see the animation below.

_{Let’s Talk Respiratory is organised and funded by Teva Pharmaceuticals and intended for healthcare professionals only. Information in the video/article may discuss drug classes where Teva have a product or products that are not authorised in all countries. Please consult local prescribing information.}